Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annu... (cogen.com target

Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting

Date:5/15/2008

cogen.com" target="_new">http://www.dacogen.com for full prescribing information.

About Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care.

Eisai Corporation of North America supports the activities of its operating companies in North America, which include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; MGI PHARMA, INC., an R&D and commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery.

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. GeoVax Secures $10 Million Financing Commitment
2. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
3. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
4. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
5. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
6. Release of Cytopia Abstract for CYT997 Oral Presentation at American Society of Clinical Oncology
7. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
8. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
9. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
10. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
11. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing

Post Your Comments:

(Date:12/16/2009)... Dec. 16 Medlytix, a national healthcare ... a key half-billion dollar milestone - the total ... provided in financial assistance to more than a ... of properly classifying charity care - in less ... of these hospitals enhanced their bottom lines and ...

(Date:12/16/2009)... Texas, Dec. 16 Wound Management ... rapidly growing provider of specialty medical products, ... subsidiary is moving toward productization of its ... company currently anticipates products to be introduced ... estimated to be a multi-billion dollar international ...

(Date:12/16/2009)... -- Ethicon, Inc., a Johnson & Johnson (NYSE: ... leader in surgical care, and Acclarent, Inc., a ... developing and commercializing devices that address conditions affecting ... a definitive merger agreement whereby Ethicon will acquire ... million net of estimated cash on hand at ...

Breaking Medicine Technology:Healthcare Scoring System Allows Hospitals To Increase Charity Care 2 Healthcare Scoring System Allows Hospitals To Increase Charity Care 3 Healthcare Scoring System Allows Hospitals To Increase Charity Care 4 Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics 2 Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics 3 Ethicon Announces Definitive Agreement to Acquire Acclarent 2 Ethicon Announces Definitive Agreement to Acquire Acclarent 3 Ethicon Announces Definitive Agreement to Acquire Acclarent 4 EPA 3A Greenhouse Gases Hazardous to Your Health 62775 1 EPA 3A Greenhouse Gases Hazardous to Your Health 62775 2 EPA 3A Greenhouse Gases Hazardous to Your Health 62775 3 Health Reform is About You and Me Not One or the Other 62773 1 Health Reform is About You and Me Not One or the Other 62773 2 Health Reform is About You and Me Not One or the Other 62773 3 Oncologist at the Childrens Hospital of Philadelphia to Chair International Childhood Cancer Organization 62771 1 Oncologist at the Childrens Hospital of Philadelphia to Chair International Childhood Cancer Organization 62771 2 Oncologist at the Childrens Hospital of Philadelphia to Chair International Childhood Cancer Organization 62771 3 Oncologist at the Childrens Hospital of Philadelphia to Chair International Childhood Cancer Organization 62771 4

[0] Healthcare Scoring System Allows Hospitals To Increase Charity Care [0] Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics [0] Ethicon Announces Definitive Agreement to Acquire Acclarent

... Jan. 9 Catalyst,Pharmaceutical Partners, Inc. (Nasdaq: ... develops and commercializes prescription drugs for the,treatment of ... its patient,enrollment target in its Phase II trial ... is Catalyst,s tablet formulation of vigabatrin,being developed as ...

... indication with clinical-stage, systemically administered siRNA product ... Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering ... today announced that it has initiated patient ... evaluating its systemically administered siRNA drug candidate ...

Other Medicine Technology:Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial 2 Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial 3 Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function 2 Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function 3 Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function 4

Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function

(Date:12/17/2009)... Climate Conference in Copenhagen approaches its conclusion, negotiations ... mitigating climate change. The new ,Reducing Emissions from ... support as a central element of any new ... of global greenhouse gas emissions, this new policy ... contribution to emissions reduction. Linked to this, developed ...

(Date:12/17/2009)... Campaign Invites Personal Stories of Inspiration on How Exercise Has Helped, ... ... December 17, 2009 -- The International Health, Racquet & Sportsclub Association ... Healthier America, it is urging Americans of all ages and abilities ... to create a culture of movement in America wherein regular daily ...

(Date:12/17/2009)... screening within year of first intercourse , , THURSDAY, Dec. ... U.S. cities, about half acquire at least one of ... trichomoniasis -- within two years of becoming sexually active, ... 381 girls, aged 14 to 17, also found that ... infections. , "Depending on the organism, within four to ...

(Date:12/17/2009)... Master of Science in Human Resource Development Degree Online ... ... 2009 -- Open enrollment has begun for Villanova’s newly online ... working professionals whose busy schedules can’t accommodate a campus-based program. ... debuting online in March 2010, location is no longer a ...

(Date:12/17/2009)... DIEGO, Dec. 17 Neurocrine Biosciences, Inc. (Nasdaq: ... into a privately negotiated transaction to sell an aggregate ... affiliates of Venrock at a price of $2.09 per ... $10 million. Neurocrine expects the financing to close on ... conditions. ,, A shelf registration statement relating ...

Breaking Medicine News(10 mins):Health News:Forests take center stage at Copenhagen 2 Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 2 Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 3 Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 4 Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 5 Health News:STDs Common Among Sexually Active Teen Girls in Cities 2 Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 2 Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 3 Health News:Neurocrine Announces Sale of 4,784,689 Shares of Common Stock, to Raise Proceeds of $10 Million 2 Health News:Neurocrine Announces Sale of 4,784,689 Shares of Common Stock, to Raise Proceeds of $10 Million 3

[0] Forests take center stage at Copenhagen [0] IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active [0] STDs Common Among Sexually Active Teen Girls in Cities [0] A World-Class HR Master's Degree Is Now Within Reach – 100% Online [0] Neurocrine Announces Sale of 4,784,689 Shares of Common Stock, to Raise Proceeds of $10 Million

... Company, a life,and health insurance company, today announced ... product, ConsecoLifeOptions. The policy,provides upside potential with downside ... policy that offers the,opportunity for long-term cash buildup ... can customize their coverage levels with eight riders,that ...

... 29 The Custom Briefings,network of Bulletin News, ... Briefing, produced exclusively for the members of the ... Monday through Friday to over,14,000 Endocrine Society members, ... as diabetes and osteoporosis. Endocrine Daily,Briefing joins a ...

... Obama failed to address the issue, DENVER, ... Wednesday night, Former President Bill Clinton called,for a ... the,United States. In praising Presidential nominee Barack Obama, ... commendable global leadership in,an area in which I ...

... The following is a,statement by Matthew L. Myers, President, ... in a month, Philip Morris International has had to,withdraw ... country,after coming under international criticism for engaging in cigarette,marketing ... International has been forced to withdraw from,an August 30 ...

... chromosomal change that raises odds for malignancy, study finds ... survivors of the World War II atomic bomb blasts ... may have sparked the onset of a form of ... (PTC) is typically linked to a particular genetic mutation ...

... InterMune, Inc.,(Nasdaq: ITMN ) today announced that ... present at the Thomas Weisel Partners,Healthcare Conference in Boston ... To access a live audio webcast of the presentation, ... investor relations page of InterMune,s,corporate website at http://www.intermune.com ...

Other Medicine News:Health News:ConsecoLifeOptions Launched by Conseco Insurance Company as New Universal Life Product 2 Health News:Custom Briefings Announces Launch of Endocrine Daily Briefing 2 Health News:Bill Clinton and Other Leaders Call For 'Renewal of Battle Against AIDS' in the United States at Democratic Convention 2 Health News:Bill Clinton and Other Leaders Call For 'Renewal of Battle Against AIDS' in the United States at Democratic Convention 3 Health News:Philip Morris International Forced to Drop Another Concert Sponsorship; Philippines Health Department Applauded for Taking Action 2 Health News:Some Hiroshima Survivors at Thyroid Cancer Risk 2 Health News:Some Hiroshima Survivors at Thyroid Cancer Risk 3

ConsecoLifeOptions Launched by Conseco Insurance Company as New Universal Life Product Custom Briefings Announces Launch of Endocrine Daily Briefing Bill Clinton and Other Leaders Call For 'Renewal of Battle Against AIDS' in the United States at Democratic Convention Philip Morris International Forced to Drop Another Concert Sponsorship; Philippines Health Department Applauded for Taking Action Some Hiroshima Survivors at Thyroid Cancer Risk InterMune to Present at Thomas Weisel Partners Healthcare Conference

Excellent all-around performance in digital format - MIC-D offers an exciting new way to observe the natural world. Multiple performance features provide new ways to enjoy microscope observation....

... High speed refrigerated floor-standing centrifuge. Powerful, ... reproducibility, informative display, display in 4 ... refrigeration, true sample temperature control, imbalance ... lid interlock, current and temperature limitation, ...

... refrigerated bench-top centrifuge. Instant rotor ... JOUAN patented system, powerful, absolute ... suits all samples, maintenance-free : ... shutdown, guard barrier, dual lid ...

... Powerful programmable refrigerated ... high capacity rotors, large ... labile sample protection, true ... control, lifetime reproducibility, true ...

Medicine Products:

MIC-D Digital Microscope KR 22i High Speed Refrigerated Floor-Standing Centrifuge.CR 3i Compact Multi-Function Refrigerated Bench-Top Centrifuge.CR 4.22 Powerful Programmable Refrigerated Bench-Top Centrifuge.

Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annu...(cogen.com target _new http://www.dacoge...),Health